Extra pill after treatment could stop deadly head & neck Cancer's return
NCT ID NCT07248670
Summary
This study is for people with a specific, high-risk type of nasopharyngeal cancer (a cancer in the upper throat). All participants get the standard treatment of chemotherapy and radiation together. For those whose blood tests still show signs of the cancer virus during treatment, the study randomly assigns them to either take a low-dose oral chemotherapy pill (capecitabine) for a period after standard treatment or to just be observed. The goal is to see if this extra pill helps keep the cancer from coming back and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
Conditions
Explore the condition pages connected to this study.